RWE Expert Discusses Ripple Effects of FDA Framework Throughout Pharma

In a recent interview, Roche’s Global Head of Real World Evidence (RWE) and Market Access Sreeram Ramagopalan shared his thoughts on the evolving role of RWE in pharma.

“In this ‘RWE in pharma’ interview series, we are putting various pharma experts in the spotlight and asking them to share their insight on how their industry has traditionally employed real-world evidence (RWE), how they envision this changing over the next few years and what their predictions of the impacts of the highly anticipated US FDA RWE Framework may be.” Read more here.

(Source: Sreeram Ramagopalan, The Evidence Base, 9/17/21)